Biochemical characterization of a recombinant TRIM5α protein that restricts human immunodeficiency virus type 1 replication

Journal of Virology

Volumn 82, Issue 23, 2008, Pages 11682-11694

  Langelier, Charles R ^a   Sandrin, Virginie ^a   Eckert, Debra M ^a   Christensen, Devin E ^a   Chandrasekaran, Viswanathan ^a   Alam, Steven L ^a   Aiken, Christopher ^b   Olsen, John C ^c   Kar, Alak Kanti ^d   Sodroski, Joseph G ^d   Sundquist, Wesley I ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; RECOMBINANT PROTEIN; TRIPARTITE MOTIF PROTEIN 21; TRIPARTITE MOTIF PROTEIN 5; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION; RING FINGER MOTIF; VIRUS CAPSID; VIRUS PARTICLE; VIRUS REPLICATION;

CAPSID; DIMERIZATION; DNA-BINDING PROTEINS; HELA CELLS; HIV-1; HUMANS; NUCLEAR PROTEINS; NUCLEOCAPSID; PROTEIN STRUCTURE, TERTIARY; PROTEINS; RECOMBINANT FUSION PROTEINS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; VIRUS REPLICATION;

EQUINE INFECTIOUS ANEMIA VIRUS; HEXAPODA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; MAMMALIA; MIRIDAE;

EID: 56449100435     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01562-08     Document Type: Article

References (74)

1. Accola, M. A., A. Ohagen, and H. G. Gottlinger. 2000. Isolation of human immunodeficiency virus type 1 cores: retention of Vpr in the absence of p6(gag). J. Virol. 74:6198-6202.
2. Anderson, J. L., E. M. Campbell, X. Wu, N. Vandegraaff, A. Engelman, and T. J. Hope. 2006. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J. Virol. 80:9754-9760.
3. Bieniasz, P. D. 2004. Intrinsic immunity: a front-line defense against viral attack. Nat. Immunol. 5:1109-1115.
4. Briggs, J. A., T. Wilk, R. Welker, H. G. Krausslich, and S. D. Fuller. 2003. Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 22:1707-1715.
5. Brzovic, P. S., A. Lissounov, D. E. Christensen, D. W. Hoyt, and R. E. Klevit. 2006. A UbcH5/ubiquitin noncovalent complex is required for processive BRCA1-directed ubiquitination. Mol. Cell 21:873-880.
6. Campbell, E. M., O. Perez, J. L. Anderson, and T. J. Hope. 2008. Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5α. J. Cell Biol. 180:549-561.
7. Campbell, S., and V. M. Vogt. 1995. Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J. Virol. 69:6487-6497.
8. Christensen, D. E., P. S. Brzovic, and R. E. Klevit. 2007. E2-BRCA1 RING interactions dictate synthesis of mono- or specific polyubiquitin chain linkages. Nat. Struct. Mol. Biol. 14:941-948.
9. Cole, J. L. 2004. Analysis of heterogeneous interactions. Methods Enzymol. 384:212-232.
10. Diaz-Griffero, F., A. Kar, M. Lee, M. Stremlau, E. Poeschla, and J. Sodroski. 2007. Comparative requirements for the restriction of retrovirus infection by TRIM5α and TRIMCyp. Virology 369:400-410.
11. Diaz-Griffero, F., A. Kar, M. Perron, S. H. Xiang, H. Javanbakht, X. Li, and J. Sodroski. 2007. Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5α B-box 2 domain. J. Virol. 81:10362-10378.
12. Diaz-Griffero, F., X. Li, H. Javanbakht, B. Song, S. Welikala, M. Stremlau, and J. Sodroski. 2006. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 349:300-315.
13. Diaz-Griffero, F., N. Vandegraaff, Y. Li, K. McGee-Estrada, M. Stremlau, S. Welikala, Z. Si, A. Engelman, and J. Sodroski. 2006. Requirements for capsid-binding and an effector function in TRIMCyp-mediated restriction of HIV-1. Virology 351:404-419.
14. Dodding, M. P., M. Bock, M. W. Yap, and J. P. Stoye. 2005. Capsid processing requirements for abrogation of fv1 and ref1 restriction. J. Virol. 79:10571-10577.
15. Fisher, R. J., A. Rein, M. Fivash, M. A. Urbaneja, J. R. Casas-Finet, M. Medaglia, and L. E. Henderson. 1998. Sequence-specific binding of human immunodeficiency virus type 1 nucleocapsid protein to short oligonucleotides. J. Virol. 72:1902-1909.
16. Forshey, B. M., J. Shi, and C. Aiken. 2005. Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. J. Virol. 79:869-875.
17. Forshey, B. M., U. von Schwedler, W. I. Sundquist, and C. Aiken. 2002. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 76:5667-5677.
18. Gamble, T. R., F. F. Vajdos, S. Yoo, D. K. Worthylake, M. Houseweart, W. I. Sundquist, and C. P. Hill. 1996. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87:1285-1294.
19. Ganser-Pornillos, B. K., A. Cheng, and M. Yeager. 2007. Structure of full-length HIV-1 CA: a model for the mature capsid lattice. Cell 131:70-79.
20. Ganser-Pornillos, B. K., M. Yeager, and W. I. Sundquist. 2008. The structural biology of HIV assembly. Curr. Opin. Struct. Biol. 18:203-217.
21. Ganser, B. K., S. Li, V. Y. Klishko, J. T. Finch, and W. I. Sundquist. 1999. Assembly and analysis of conical models for the HIV-1 core. Science 283:80-83.
22. Hatfield, P. M., J. Callis, and R. D. Vierstra. 1990. Cloning of ubiquitin activating enzyme from wheat and expression of a functional protein in Escherichia coli. J. Biol. Chem. 265:15813-15817.
23. Hatziioannou, T., S. Cowan, S. P. Goff, P. D. Bieniasz, and G. J. Towers. 2003. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22:385-394.
24. Hennig, J., A. Bresell, M. Sandberg, K. D. Hennig, M. Wahren-Herlenius, B. Persson, and M. Sunnerhagen. 2008. The fellowship of the RING: the RING-B-box linker region interacts with the RING in TRIM21/Ro52, contains a native autoantigenic epitope in Sjogren syndrome, and is an integral and conserved region in TRIM proteins. J. Mol. Biol. 377:431-449.
25. James, L. C., A. H. Keeble, Z. Khan, D. A. Rhodes, and J. Trowsdale. 2007. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc. Natl. Acad. Sci. USA 104:6200-6205.
26. Javanbakht, H., F. Diaz-Griffero, M. Stremlau, Z. Si, and J. Sodroski. 2005. The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5α. J. Biol. Chem. 280:26933- 26940.
27. Javanbakht, H., W. Yuan, D. F. Yeung, B. Song, F. Diaz-Griffero, Y. Li, X. Li, M. Stremlau, and J. Sodroski. 2006. Characterization of TRIM5α trimerization and its contribution to human immunodeficiency virus capsid binding. Virology 353:234-246.
28. Jin, Z., L. Jin, D. L. Peterson, and C. L. Lawson. 1999. Model for lentivirus capsid core assembly based on crystal dimers of EIAV p26. J. Mol. Biol. 286:83-93.
29. Keckesova, Z., L. M. Ylinen, and G. J. Towers. 2004. The human and African green monkey TRIM5α genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. USA 101:10780- 10785.
30. Kotov, A., J. Zhou, P. Flicker, and C. Aiken. 1999. Association of Nef with the human immunodeficiency virus type 1 core. J. Virol. 73:8824-8830.
31. Laue, T., B. Shah, T. Ridgeway, and S. Pelletier. 1992. Computer-aided interpretation of analytical sedimentation data for proteins, p. 90-125. In A. Rowe and J. Horton (ed.), Ultracentrifugation in biochemistry and polymer science. Royal Society of Chemistry, Cambridge, England.
32. Li, S., C. P. Hill, W. I. Sundquist, and J. T. Finch. 2000. Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407:409-413.
33. Li, X., B. Gold, C. O'Huigin, F. Diaz-Griffero, B. Song, Z. Si, Y. Li, W. Yuan, M. Stremlau, C. Mische, H. Javanbakht, M. Scally, C. Winkler, M. Dean, and J. Sodroski. 2006. Unique features of TRIM5α among closely related human TRIM family members. Virology 360:419-433.
34. Li, Y., X. Li, M. Stremlau, M. Lee, and J. Sodroski. 2006. Removal of arginine 332 allows human TRIM5α to bind human immunodeficiency virus capsids and to restrict infection. J. Virol. 80:6738-6744.
35. Liu, H. L., Y. Q. Wang, C. H. Liao, Y. Q. Kuang, Y. T. Zheng, and B. Su. 2005. Adaptive evolution of primate TRIM5α, a gene restricting HIV-1 infection. Gene 362:109-116.
36. Mische, C. C., H. Javanbakht, B. Song, F. Diaz-Griffero, M. Stremlau, B. Strack, Z. Si, and J. Sodroski. 2005. Retroviral restriction factor TRIM5α is a trimer. J. Virol. 79:14446-14450.
37. Nisole, S., and A. Saib. 2004. Early steps of retrovirus replicative cycle. Retrovirology 1:9.
38. Ohkura, S., M. W. Yap, T. Sheldon, and J. P. Stoye. 2006. All three variable regions of the TRIM5α B30.2 domain can contribute to the specificity of retrovirus restriction. J. Virol. 80:8554-8565.
39. O'Rourke, J. P., J. C. Olsen, and B. A. Bunnell. 2005. Optimization of equine infectious anemia derived vectors for hematopoietic cell lineage gene transfer. Gene Ther. 12:22-29.
40. Ottosson, L., J. Hennig, A. Espinosa, S. Brauner, M. Wahren-Herlenius, and M. Sunnerhagen. 2006. Structural, functional, and immunologic characterization of folded subdomains in the Ro52 protein targeted in Sjogren's syndrome. Mol. Immunol. 43:588-598.
41. Perez-Caballero, D., T. Hatziioannou, A. Yang, S. Cowan, and P. D. Bieniasz. 2005. Human tripartite motif 5α domains responsible for retrovirus restriction activity and specificity. J. Virol. 79:8969-8978.
42. Perron, M. J., M. Stremlau, M. Lee, H. Javanbakht, B. Song, and J. Sodroski. 2007. The human TRIM5α restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J. Virol. 81:2138-2148.
43. Perron, M. J., M. Stremlau, B. Song, W. Ulm, R. C. Mulligan, and J. Sodroski. 2004. TRIM5α mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. USA 101:11827-11832.
44. Pickart, C. M., and S. Raasi. 2005. Controlled synthesis of polyubiquitin chains. Methods Enzymol. 399:21-36.
45. Rhodes, D. A., and J. Trowsdale. 2007. TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. Mol. Immunol. 44:2406-2414.
46. Roberts, M. M., and S. Oroszlan. 1989. The preparation and biochemical characterization of intact capsids of equine infectious anemia virus. Biochem. Biophys. Res. Commun. 160:486-494.
47. Rold, C. J., and C. Aiken. 2008. Proteasomal degradation of TRIM5α during retrovirus restriction. PLoS Pathog. 4:e1000074.
48. Sandrin, V., and F. L. Cosset. 2006. Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein. J. Biol. Chem. 281:528-542.
49. Sanes, J. R., J. L. Rubenstein, and J. F. Nicolas. 1986. Use of recombinant retrovirus to study post-implantation cell lineage in mouse embryos. Embo J. 5:3133-3142.
50. Sawyer, S. L., M. Emerman, and H. S. Malik. 2007. Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS Pathog. 3:e197.
51. Sawyer, S. L., L. I. Wu, M. Emerman, and H. S. Malik. 2005. Positive selection of primate TRIM5α identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. USA 102:2832-2837.
52. Sebastian, S., and J. Luban. 2005. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2:40.
53. Shi, J., and C. Aiken. 2006. Saturation of TRIM5α-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. Virology 350:493-500.
54. Song, B., F. Diaz-Griffero, D. H. Park, T. Rogers, M. Stremlau, and J. Sodroski. 2005. TRIM5α association with cytoplasmic bodies is not required for antiretroviral activity. Virology 343:201-211.
55. Song, B., B. Gold, C. O'Huigin, H. Javanbakht, X. Li, M. Stremlau, C. Winkler, M. Dean, and J. Sodroski. 2005. The B30.2(SPRY) domain of the retroviral restriction factor TRIM5α exhibits lineage-specific length and sequence variation in primates. J. Virol. 79:6111-6121.
56. Stremlau, M., C. M. Owens, M. J. Perron, M. Kiessling, P. Autissier, and J. Sodroski. 2004. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.
57. Stremlau, M., M. Perron, M. Lee, Y. Li, B. Song, H. Javanbakht, F. Diaz-Griffero, D. J. Anderson, W. I. Sundquist, and J. Sodroski. 2006. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5α restriction factor. Proc. Natl. Acad. Sci. USA 103:5514- 5519.
58. Stremlau, M., M. Perron, S. Welikala, and J. Sodroski. 2005. Species-specific variation in the B30.2(SPRY) domain of TRIM5α determines the potency of human immunodeficiency virus restriction. J. Virol. 79:3139-3145.
59. Towers, G. J. 2007. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 4:40.
60. Wang, D., J. P. Buyon, Z. Yang, F. Di Donato, M. E. Miranda-Carus, and E. K. Chan. 2001. Leucine zipper domain of 52 kDa SS-A/Ro promotes protein dimer formation and inhibits in vitro transcription activity. Biochim. Biophys. Acta 1568:155-161.
61. Ward, D. M., M. B. Vaughn, S. L. Shiflett, P. L. White, A. L. Pollock, J. Hill, R. Schnegelberger, W. I. Sundquist, and J. Kaplan. 2005. The role of LIP5 and CHMP5 in multivesicular body formation and HIV-1 budding in mammalian cells. J. Biol. Chem. 280:10548-10555.
62. Welker, R., H. Hohenberg, U. Tessmer, C. Huckhagel, and H. G. Krausslich. 2000. Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. J. Virol. 74:1168-1177.
63. Woo, J. S., H. Y. Suh, S. Y. Park, and B. H. Oh. 2006. Structural basis for protein recognition by B30.2/SPRY domains. Mol. Cell 24:967-976.
64. Wu, X., J. L. Anderson, E. M. Campbell, A. M. Joseph, and T. J. Hope. 2006. Proteasome inhibitors uncouple rhesus TRIM5α restriction of HIV-1 reverse transcription and infection. Proc. Natl. Acad. Sci. USA 103:7465-7470.
65. Xu, L., L. Yang, P. K. Moitra, K. Hashimoto, P. Rallabhandi, S. Kaul, G. Meroni, J. P. Jensen, A. M. Weissman, and P. D'Arpa. 2003. BTBD1 and BTBD2 colocalize to cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5. Exp. Cell Res. 288:84-93.
66. Yamauchi, K., K. Wada, K. Tanji, M. Tanaka, and T. Kamitani. 2008. Ubiquitination of E3 ubiquitin ligase TRIM5α and its potential role. FEBS J. 275:1540-1555.
67. Yap, M. W., M. P. Dodding, and J. P. Stoye. 2006. Trim-cyclophilin A fusion proteins can restrict human immunodeficiency virus type 1 infection at two distinct phases in the viral life cycle. J. Virol. 80:4061-4067.
68. Yap, M. W., G. B. Mortuza, I. A. Taylor, and J. P. Stoye. 2007. The design of artificial retroviral restriction factors. Virology 365:302-314.
69. Yap, M. W., S. Nisole, C. Lynch, and J. P. Stoye. 2004. Trim5α protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. USA 101:10786-10791.
70. Yap, M. W., S. Nisole, and J. P. Stoye. 2005. A single amino acid change in the SPRY domain of human Trim5α leads to HIV-1 restriction. Curr. Biol. 15:73-78.
71. Yee, J. K., A. Miyanohara, P. LaPorte, K. Bouic, J. C. Burns, and T. Friedmann. 1994. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA 91:9564-9568.
72. Yoo, S., D. G. Myszka, C. Yeh, M. McMurray, C. P. Hill, and W. I. Sundquist. 1997. Molecular recognition in the HIV-1 capsid/cyclophilin A complex. J. Mol. Biol. 269:780-795.
73. Zhang, F., T. Hatziioannou, D. Perez-Caballero, D. Derse, and P. D. Bieniasz. 2006. Antiretroviral potential of human tripartite motif-5 and related proteins. Virology 353:396-409.
74. Zhang, M., M. Windheim, S. M. Roe, M. Peggie, P. Cohen, C. Prodromou, and L. H. Pearl. 2005. Chaperoned ubiquitylation: crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex. Mol. Cell 20:525-538.